ethyl 4-oxo-1-({4-[4-(trifluoroethyl)phenyl]piperidin-1-yl}methyl)-4H-quinolizine-3-carboxylate | 1181965-76-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ethyl 4-oxo-1-({4-[4-(trifluoroethyl)phenyl]piperidin-1-yl}methyl)-4H-quinolizine-3-carboxylate
• 英文别名: ethyl 4-oxo-1-({4-[4-(trifluoromethyl)phenyl]piperidin-1-yl}methyl)-4H-quinolizine-3-carboxylate；ethyl 4-oxo-1-[[4-[4-(trifluoromethyl)phenyl]piperidin-1-yl]methyl]quinolizine-3-carboxylate
• CAS: 1181965-76-3
• 化学式: C₂₅H₂₅F₃N₂O₃
• 分子量: 458.48
• InChiKey: ZBECBPNTQXXZQF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  ethyl 4-oxo-1-({4-[4-(trifluoroethyl)phenyl]piperidin-1-yl}methyl)-4H-quinolizine-3-carboxylate 在 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 66.0h， 生成 4-oxo-1-({4-[4-(trifiuoromethyl)phenyl]piperidin-1-yl}methyl)-4H-quinolizine-3-carboxylic acid sodium salt
  参考文献：
  名称：

  [EN] QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  [FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 DE QUINOLIZIDINONE

  摘要：

  本发明涉及式(I)的化合物，它们是M1受体正向变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。本发明还涉及包含该化合物的制药组合物，以及在治疗M1受体介导的疾病中使用该化合物和组合物的用途。

  公开号：

  WO2009102574A1
• 作为产物：
  描述：

  乙基4-氧代-4H-喹嗪-3-羧酸酯 在 三乙酰氧基硼氢化钠 、 溶剂黄146 、 三氯氧磷 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 ethyl 4-oxo-1-({4-[4-(trifluoroethyl)phenyl]piperidin-1-yl}methyl)-4H-quinolizine-3-carboxylate
  参考文献：
  名称：

  Quinolizidinone carboxylic acid selective M1 allosteric modulators: SAR in the piperidine series

  摘要：

  SAR study of the piperidine moiety in a series of quinolizidinone carboxylic acid M1 positive allosteric modulators was examined. While the SAR was generally flat, compounds were identified with high CNS exposure to warrant additional in vivo evaluation. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.094

文献信息

• Quinolizidinone M1 receptor positive allosteric modulators
  申请人：Merck Sharp & Dohme Corp.

  公开号：US08288409B2

  公开（公告）日：2012-10-16

  The present invention is directed to compounds of formula (I) (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的化合物(I)，它们是M1受体正向变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含该化合物的制药组合物，以及在治疗M1受体介导的疾病中使用该化合物和组合物的方法。
• Quinolizidinone M1 Receptor Positive Allosteric Modulators
  申请人：Kuduk Scott D.

  公开号：US20100324024A1

  公开（公告）日：2010-12-23

  The present invention is directed to compounds of formula (I) (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及公式（I）的化合物（I），它们是M1受体正向变构调节剂，可用于治疗涉及M1受体的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含这些化合物的制药组合物，以及利用这些化合物和组合物治疗M1受体介导的疾病的用途。
• QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2252151B1

  公开（公告）日：2014-05-14
• US8288409B2
  申请人：——

  公开号：US8288409B2

  公开（公告）日：2012-10-16
• Quinolizidinone carboxylic acid selective M1 allosteric modulators: SAR in the piperidine series
  作者：Scott D. Kuduk、Ronald K. Chang、Christina N. Di Marco、William J. Ray、Lei Ma、Marion Wittmann、Matthew A. Seager、Kenneth A. Koeplinger、Charles D. Thompson、George D. Hartman、Mark T. Bilodeau

  DOI：10.1016/j.bmcl.2011.01.094

  日期：2011.3

  SAR study of the piperidine moiety in a series of quinolizidinone carboxylic acid M1 positive allosteric modulators was examined. While the SAR was generally flat, compounds were identified with high CNS exposure to warrant additional in vivo evaluation. (C) 2011 Elsevier Ltd. All rights reserved.